STOCK TITAN

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company specializing in cancer treatment, has scheduled its full year 2024 financial results conference call and webcast for March 27, 2025, at 8:00 AM ET. The presentation will include both financial performance review and clinical programs updates.

Investors can access the call through domestic (1-877-704-4453) or international (1-201-389-0920) dial-in numbers. A webcast option is also available, and the presentation will be archived on the company's website for six months following the live event.

PDS Biotechnology (Nasdaq: PDSB), un'azienda di immunoterapia in fase avanzata specializzata nel trattamento del cancro, ha programmato la sua call e webcast sui risultati finanziari dell'intero anno 2024 per il 27 marzo 2025, alle 8:00 AM ET. La presentazione includerà una revisione delle performance finanziarie e aggiornamenti sui programmi clinici.

Gli investitori possono accedere alla call tramite i numeri di telefono nazionali (1-877-704-4453) o internazionali (1-201-389-0920). È disponibile anche un'opzione di webcast e la presentazione sarà archiviata sul sito web dell'azienda per sei mesi dopo l'evento dal vivo.

PDS Biotechnology (Nasdaq: PDSB), una empresa de inmunoterapia en etapa avanzada especializada en el tratamiento del cáncer, ha programado su conferencia y webcast sobre los resultados financieros del año completo 2024 para el 27 de marzo de 2025, a las 8:00 AM ET. La presentación incluirá tanto una revisión del rendimiento financiero como actualizaciones de los programas clínicos.

Los inversores pueden acceder a la llamada a través de números de marcado nacionales (1-877-704-4453) o internacionales (1-201-389-0920). También hay una opción de webcast, y la presentación se archivará en el sitio web de la empresa durante seis meses después del evento en vivo.

PDS Biotechnology (Nasdaq: PDSB), 암 치료를 전문으로 하는 후기 단계 면역 요법 회사는 2024년 전체 회계 연도 재무 결과에 대한 컨퍼런스 콜 및 웹캐스트를 2025년 3월 27일 오전 8시 ET로 예정하고 있습니다. 발표에는 재무 성과 검토 및 임상 프로그램 업데이트가 포함됩니다.

투자자는 국내 전화번호(1-877-704-4453) 또는 국제 전화번호(1-201-389-0920)를 통해 콜에 접속할 수 있습니다. 웹캐스트 옵션도 제공되며, 발표는 라이브 이벤트 이후 6개월 동안 회사 웹사이트에 아카이브됩니다.

PDS Biotechnology (Nasdaq: PDSB), une entreprise d'immunothérapie en phase avancée spécialisée dans le traitement du cancer, a programmé sa conférence téléphonique et webcast sur les résultats financiers de l'année complète 2024 pour le 27 mars 2025 à 8h00 ET. La présentation comprendra un examen des performances financières ainsi que des mises à jour sur les programmes cliniques.

Les investisseurs peuvent accéder à l'appel via des numéros de téléphone nationaux (1-877-704-4453) ou internationaux (1-201-389-0920). Une option de webcast est également disponible, et la présentation sera archivée sur le site Web de l'entreprise pendant six mois après l'événement en direct.

PDS Biotechnology (Nasdaq: PDSB), ein Unternehmen für Immuntherapie in der späten Phase, das sich auf die Krebsbehandlung spezialisiert hat, hat seine Konferenzschaltung und Webcast zu den finanziellen Ergebnissen für das gesamte Jahr 2024 für den 27. März 2025 um 8:00 Uhr ET angesetzt. Die Präsentation umfasst sowohl eine Überprüfung der finanziellen Leistung als auch Aktualisierungen zu klinischen Programmen.

Investoren können über nationale (1-877-704-4453) oder internationale (1-201-389-0920) Einwahlnummern auf die Konferenz zugreifen. Eine Webcast-Option ist ebenfalls verfügbar, und die Präsentation wird für sechs Monate nach der Live-Veranstaltung auf der Website des Unternehmens archiviert.

Positive
  • None.
Negative
  • None.

PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the year ended December 31, 2024, and provide a clinical programs update on Thursday, March 27, 2025, at 8:00 a.m. Eastern Time.

Conference Call Details

Date: March 27, 2025
Time: 8:00 a.m. Eastern Time
Dial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)
Webcast Registration: Click Here
Call Me™ Registration: Click Here (Available 15 minutes prior to call)

After the live webcast, the event will be archived on PDS Biotech’s website for six months.

About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.

For more information, please visit www.pdsbiotech.com

Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to conduct planned clinical trials for Versamune® HPV, PDS01ADC, Versamune® MUC1 and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning Versamune® HPV, PDS01ADC, Versamune® MUC1 and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. 

Versamune® is a registered trademark of PDS Biotechnology Corporation.

Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:
Janine McCargo
6 Degrees
Phone +1 (646) 528-4034
Email: jmccargo@6degreespr.com


FAQ

When will PDS Biotech (PDSB) release its full year 2024 financial results?

PDS Biotech will release its full year 2024 financial results on March 27, 2025, at 8:00 AM Eastern Time.

How can investors access PDS Biotech's (PDSB) 2024 earnings call?

Investors can join via phone (1-877-704-4453 domestic, 1-201-389-0920 international) or through the webcast link available on the company's website.

How long will PDS Biotech's (PDSB) 2024 earnings webcast be available?

The webcast will be archived on PDS Biotech's website for six months after the live event.

What topics will be covered in PDS Biotech's (PDSB) upcoming earnings call?

The call will cover full year 2024 financial results and provide updates on the company's clinical programs.
Pds Biotechnology Corporation

NASDAQ:PDSB

PDSB Rankings

PDSB Latest News

PDSB Stock Data

45.39M
44.00M
3.11%
9.57%
10.48%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON